for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vertex Pharmaceuticals Incorporated

VRTX.OQ

Latest Trade

215.01USD

Change

1.85(+0.87%)

Volume

403,515

Today's Range

213.81

 - 

216.77

52 Week Range

202.62

 - 

306.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
213.16
Open
213.81
Volume
403,515
3M AVG Volume
38.85
Today's High
216.77
Today's Low
213.81
52 Week High
306.08
52 Week Low
202.62
Shares Out (MIL)
258.87
Market Cap (MIL)
55,658.71
Forward P/E
19.51
Dividend (Yield %)
--

Next Event

Vertex Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Vertex And Obsidian Therapeutics Establish Collaboration To Discover Novel Therapies That Regulate Gene Editing

Vertex Pharma And Crispr Amend Collaboration For Development, Manufacturing And Commercialization Of CTX001 In Sickle Cell Disease And Beta Thalassemia

Vertex Announces FDA Fast Track Designation For VX-880

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry

Biotechnology & Drugs

Contact Info

50 Northern Ave

BOSTON, MA

02210-1862

United States

+1.617.3416393

https://www.vrtx.com/

Executive Leadership

Jeffrey M. Leiden

Executive Chairman of the Board

Reshma Kewalramani

President, Chief Executive Officer, Director

Charles F. Wagner

Chief Financial Officer, Executive Vice President

Michael J. Parini

Executive Vice President, Chief Administrative, Legal and Business Development Officer

David Altshuler

Executive Vice President - Global Research, Chief Scientific Officer

Key Stats

1.84 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.0K

2019

4.0K

2020

6.2K

2021(E)

7.0K
EPS (USD)

2018

4.080

2019

5.330

2020

10.320

2021(E)

11.021
Price To Earnings (TTM)
20.46
Price To Sales (TTM)
8.68
Price To Book (MRQ)
6.20
Price To Cash Flow (TTM)
19.37
Total Debt To Equity (MRQ)
5.91
LT Debt To Equity (MRQ)
5.91
Return on Investment (TTM)
31.52
Return on Equity (TTM)
26.29

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up